**will not be participating in the webinar or eBriefing

Available via
WEBINAR
FREE
for Members
Long Acting HIV Prevention Methods
Friday, September 22, 2017
Presented By
The Bill & Melinda Gates Foundation
Microbiology and Infectious Diseases Discussion Group
The New York Academy of Sciences
The development of antiretroviral drugs for HIV has dramatically reduced disease burden for millions of people with access to adequate treatment and prevention programs. However, UNAIDS reports that 25 million people in Sub-Saharan Africa are still living with HIV, accounting for more than two-thirds of the infected population worldwide, and that women (aged 15-24) in this region are disproportionately impacted. Importantly, the number of young women at the cusp of this age range is currently very high, placing us at an important juncture. Without adequate intervention and a reduction in the rate of new infections, the most likely outcome is a resurgence of the HIV epidemic.
The scientific community must develop new and effective prevention strategies to reduce HIV transmission in order to prevent this devastating outcome. Taking into consideration economic, social, and cultural barriers to current HIV prevention strategies, approaches such as long-acting therapies are a promising path forward, however key questions remain before this approach can be put to use in community settings. This conference will address current scientific barriers to development of long-acting prevention methods for HIV.
Registration for this conference is FREE.
Registration
Friday
September 22, 2017
Session 1: The Challenge of Effective Anti-HIV Biomedical Prevention
Opening Remarks
Speakers
Control of the HIV Epidemic: The Challenges and the Potential for Failure
Speaker
Learnings from the Use of Currently Available Biomedical Interventions
Speaker
Q&A/Discussion
Speakers
Networking Coffee Break
Session 2: Novel Small Molecule Prevention Interventions
Cabotegravir Long-Acting (CAB LA) Intramuscular Injectable Suspension: A New Candidate for HIV Prevention
Speaker
Promising Single Agent ARVs for Prevention
Speaker
Dapivirine Ring: Clinical Data and Delivery Plans
Speaker
Q&A/Discussion
Speakers
Lunch
Session 3: Drug Delivery Technologies
Challenges of Developing Sustained Release Formulations of Antiretrovirals for PrEP
Speaker
Self-Assembled Hydrogels as Long-Acting Injectables
Speaker
Q&A/Discussion
Speakers
Networking Coffee Break
Session 4: Novel Biological Interventions
Clinical Development HIV-1 bNAbs for Prevention
Speaker
Broadly Neutralizing Antibodies for HIV Prevention
Speaker
Development of PGT121 and PGDM1400
Speaker
Optimizing bnAbs for Manufacturability and Stability
Speaker
Q&A/Discussion
Speakers
Closing Remarks
Speaker